TY - JOUR
T1 - Direct cardiac reprogramming
T2 - A novel approach for heart regeneration
AU - Tani, Hidenori
AU - Sadahiro, Taketaro
AU - Ieda, Masaki
N1 - Funding Information:
Funding: Masaki Ieda received research grants from the Advanced Research & Development Programs for Medical Innovation solo-type, the Research Center Network for Realization of Regenerative Medicine, and the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED), the Japan Society for the Promotion of Science (JSPS), Takeda Science Foundation, and Daiichi-Sankyo Foundation of Life Science.
Publisher Copyright:
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2018/9/5
Y1 - 2018/9/5
N2 - Cardiac diseases are among the most common causes of death globally. Cardiac muscle has limited proliferative capacity, and regenerative therapies are highly in demand as a new treatment strategy. Although pluripotent reprogramming has been developed, it has obstacles, such as a potential risk of tumor formation, poor survival of the transplanted cells, and high cost. We previously reported that fibroblasts can be directly reprogrammed to cardiomyocytes by overexpressing a combination of three cardiac-specific transcription factors (Gata4, Mef2c, Tbx5 (together, GMT)). We and other groups have promoted cardiac reprogramming by the addition of certain miRNAs, cytokines, and epigenetic factors, and unraveled new molecular mechanisms of cardiac reprogramming. More recently, we discovered that Sendai virus (SeV) vector expressing GMT could efficiently and rapidly reprogram fibroblasts into integration-free cardiomyocytes in vitro via robust transgene expression. Gene delivery of SeV-GMT also improves cardiac function and reduces fibrosis after myocardial infarction in mice. Through direct cardiac reprogramming, new cardiomyocytes can be generated and scar tissue reduced to restore cardiac function, and, thus, direct cardiac reprogramming may serve as a powerful strategy for cardiac regeneration. Here, we provide an overview of the previous reports and current challenges in this field.
AB - Cardiac diseases are among the most common causes of death globally. Cardiac muscle has limited proliferative capacity, and regenerative therapies are highly in demand as a new treatment strategy. Although pluripotent reprogramming has been developed, it has obstacles, such as a potential risk of tumor formation, poor survival of the transplanted cells, and high cost. We previously reported that fibroblasts can be directly reprogrammed to cardiomyocytes by overexpressing a combination of three cardiac-specific transcription factors (Gata4, Mef2c, Tbx5 (together, GMT)). We and other groups have promoted cardiac reprogramming by the addition of certain miRNAs, cytokines, and epigenetic factors, and unraveled new molecular mechanisms of cardiac reprogramming. More recently, we discovered that Sendai virus (SeV) vector expressing GMT could efficiently and rapidly reprogram fibroblasts into integration-free cardiomyocytes in vitro via robust transgene expression. Gene delivery of SeV-GMT also improves cardiac function and reduces fibrosis after myocardial infarction in mice. Through direct cardiac reprogramming, new cardiomyocytes can be generated and scar tissue reduced to restore cardiac function, and, thus, direct cardiac reprogramming may serve as a powerful strategy for cardiac regeneration. Here, we provide an overview of the previous reports and current challenges in this field.
KW - Cardiac regeneration
KW - Cardiomyocytes
KW - Direct reprogramming
KW - Fibroblasts
KW - Gene therapy
UR - http://www.scopus.com/inward/record.url?scp=85053076378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053076378&partnerID=8YFLogxK
U2 - 10.3390/ijms19092629
DO - 10.3390/ijms19092629
M3 - Review article
C2 - 30189626
AN - SCOPUS:85053076378
SN - 1661-6596
VL - 19
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 9
M1 - 2629
ER -